The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, solvate, hydrate or pharmaceutically acceptable formulation thereof. Those compounds can be used in inhibiting factor Xa and in the prevention and/or treatment of thromboembolic conditions.